SMAD4 and prostate carcinoma: In this model, enhanced activation of the PI3K pathway and increased levels of Smad4 protein were observed, whereas reduced Smad4 expression correlated with metastatic tumor progression, supporting a role of Smad4 acting as a tumor suppressor in prostate cancer (Ding et al., 2011).